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Background: Pediatric embryonal brain tumors (PEBTs), which encompass medulloblastoma (MB), primitive
neuroectodermal tumor (PNET) and atypical teratoid/rhabdoid tumor (AT/RT), are the second most prevalent
pediatric brain tumor type. AT/RT is highly malignant and is often misdiagnosed as MB or PNET. The distinction of
AT/RT from PNET/MB is of clinical significance because the survival rate of patients with AT/RT is substantially lower.
The diagnosis of AT/RT relies primarily on morphologic assessment and immunohistochemical (IHC) staining for a
few known markers such as the lack of INI1 protein expression. However, in our clinical practice we have observed
several AT/RT-like tumors, that fulfilled histopathological and all other biomarker criteria for a diagnosis of AT/RT, yet
retained INI1 immunoreactivity. Recent studies have also reported preserved INI1 immunoreactivity among certain
diagnosed AT/RTs. It is therefore necessary to re-evaluate INI1(+), AT/RT-like cases.
Method: Sanger sequencing, array CGH and mRNA microarray analyses were performed on PEBT samples to
investigate their genomic landscapes.
Results: Patients with AT/RT and those with INI(+) AT/RT-like tumors showed a similar survival rate, and global array
CGH analysis and INI1 gene sequencing showed no differential chromosomal aberration markers between INI1(−)
AT/RT and INI(+) AT/RT-like cases. We did not misdiagnose MBs or PNETs as AT/RT-like tumors because
transcriptome profiling revealed that not only did AT/RT and INI(+) AT/RT-like cases express distinct mRNA and
microRNA profiles, their gene expression patterns were different from those of MBs and PNETs. The most similar
transcriptome profile to that of AT/RTs was the profile of embryonic stem cells. However; the transcriptome profile
of INI1(+) AT/RT-like tumors was more similar to that of somatic neural stem cells, while the profile of MBs was
closer to that of fetal brain tissue. Novel biomarkers were identified that can be used to distinguish INI1(−) AT/RTs,
INI1(+) AT/RT-like cases and MBs.
Conclusion: Our studies revealed a novel INI1(+) ATRT-like subtype among Taiwanese pediatric patients. New
diagnostic biomarkers, as well as new therapeutic tactics, can be developed according to the transcriptome
data that were unveiled in this work.
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Pediatric brain tumors are second only to neoplasms of
the lymphoid-hematopoietic system in childhood in
terms of the number of cases and mortality [1, 2]. Pediatric
embryonal brain tumors (PEBTs) are the second most
prevalent type of pediatric brain tumors and include
medulloblastoma (MB), CNS primitive neuroectodermal
tumor (CNS-PNET) and atypical teratoid/rhabdoid tumor
(AT/RT). AT/RTs of the central nervous system (CNS)
were first described by Rorke et al. in 1987. This tumor
type was later recognized as a rare, highly malignant entity
of CNS embryonal tumors that predominantly occurs in
infants and young children with a peak incidence between
birth and 3 years of age [3–6]. The distinction of AT/RT
from CNS-PNET and MB is of clinical significance be-
cause the reported 2-year survival rate of patients with
AT/RTs is substantially lower than that of patients with
CNS-PNETs or MBs: in Taiwan, the reported 2-year sur-
vival rate of patients with AT/RTs is 18 %, while that of
patients with a standard-risk MB is 83.9 % [7].
Clinically, cerebellar AT/RT is often misdiagnosed as a
PNET or a MB. The diagnosis of AT/RT is based on the
presence of rhabdoid tumor cells, which are medium-sized,
round-to-oval cells with distinct borders, a large amount of
cytoplasm and eccentrically located nuclei. Other mor-
phological features include the presence of small cells with
the morphology of PNET cells as well as epithelial and
mesenchymal components [5]. AT/RT cells are immuno-
reactive for a wide range of epithelial, mesenchymal, glial
and neural markers, including epithelial membrane anti-
gen (EMA), vimentin (VIM), smooth muscle actin (SMA),
and glial fibrillary acidic protein (GFAP) [5, 7, 8]. MB cells
are negative by staining for EMA and SMA but are positive
for synaptophysin (SYN) [5, 7, 8]. The most widely known
tumor suppressor and diagnostic biomarker for AT/RT is
INI1 (also known as SMARCB1, hSNF5, BAF47). INI1 be-
longs to a core member of the ATP-dependent SWI/SNF
chromatin-remodeling complex, which is a master regula-
tor of gene expression that is involved in cancer. Genetic
studies have shown that deletion or mutation of the INI1
gene, which is located on 22q11.2, occurs in approximately
75 % [3, 9] to 98 % [10] of AT/RTs. Immunohistochemi-
cal (IHC) staining for INI1 is considered a sensitive and
highly specific approach for the diagnosis of AT/RT and
in the differentiation of this tumor type from PNET and
MB [11]. The lack of INI1 protein immunoreactivity has
been shown in 100 % [4, 9, 12] to 84 % [13] of AT/RT
cases. In contrast, retained INI1 expression (INI1 positive)
was noted in all cases of PNETs/MBs [4, 9, 11–13].
With respect to the histopathologic diagnosis of PEBT,
in our clinical practice, INI1 as well as EMA, VIM, SMA,
GFAP and SYN are included in a panel of IHC markers to
distinguish AT/RT from other PEBTs, especially MB. Un-
expectedly, we observed several AT/RT-like cases, whichfulfilled all other biomarker and histopathologic criteria
for a diagnosis of AT/RT, yet still demonstrated INI1
immunoreactivity. It is therefore necessary to understand
these atypical cases and to classify them more accurately.
For this purpose, we performed a thorough pathological
review of our PEBT cases and conducted a systemic
genomic analysis. Transcriptomic analysis was also per-
formed using fresh tissues of histopathologically con-
firmed cases.
Materials and methods
Study materials and clinical data
Study cases were retrieved from the surgical pathology files
of the Department of Pathology and Laboratory Medicine,
Taipei Veterans General Hospital (VGH-TPE), Taiwan.
The Parent/legal guardian of patients in this study pro-
vided informed consent, and all procedures were approved
by the Institutional Review Board of VGH-TPE (VGHIRB
No.:2011-11-007GA & 2011-11-008GA). Fresh tumor tis-
sues that were removed during surgery were snap-frozen
and stored in liquid nitrogen until DNA and RNA extrac-
tion. The overall survival time was calculated as the time
from surgery until death or the time from surgery until
the last follow-up appointment for the patients who sur-
vived. A Mann–Whitney test was used to compare age
differences among the different groups of patients. The
differences in survival times were assessed with the log-
rank test.
Histopathologic diagnosis of AT/RT and MB
A diagnosis of AT/RT was based on the morphologic fea-
tures of the tumor and the results of IHC, as described in
our previous reports [7, 14]. With regard to the morpho-
logic features, rhabdoid cells, which were either large, pale,
bland cells or the classical type similar to those observed
in malignant rhabdoid tumors of the kidney, were essen-
tial for diagnosis [8, 15]. Other features, such as cells that
are similar to primitive neuroectodermal cells, an epithe-
lial component and a mesenchymal component, could
also be observed. An IHC diagnostic panel included the
following markers: epithelial membrane antigen [EMA;
monoclonal, dilution 1:40, Dako, Glostrup, Denmark,
Histostain SP Broad Spectrum (HRP), Zymed Lab., Carlsbad,
USA (Histostain); antigen retrieval using a microwave,
three cycles for 5 min each (M)], vimentin (VIM; mono-
clonal, 1:600, Dako, Histostain, M), smooth muscle actin
(SMA, HHF-35; monoclonal, 1:75, Dako, Carpinteria, CA,
USA, Histostain, M), and glial fibrillary acidic protein
(GFAP; monoclonal, 1:300, Dako, Histostain, M) [5, 8, 14].
The rhabdoid cells were immunoreactive for two or more
of the above-listed antibodies. IHC for INI1 (anti-BAF47;
monoclonal, 1:40, BD Transduction Laboratories, San Diego,
CA, USA, Histostain, M) and SMARCA4 (anti-BRG1;
monoclonal, 1:100, Abcam, Cambridge, U.K., Histostain,
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a diagnosis of MB, besides the presence of the known
morphology of this tumor type, the features of AT/RT as
listed above were absent. Immunostaining for synaptophy-
sin (SYN; monoclonal, 1:50, Novocastra, Newcastle upon
Tyne, U.K., Histostain, M) was included to confirm the
diagnosis and to distinguish it from AT/RT; IHC for SYN
was also performed in all AT/RT cases. Positive and nega-
tive controls were included with each batch of sections to
confirm the consistency of the analysis in all of the stains
that were performed in this study. As for the INI1 stain-
ing, positive control consisted of endothelial cells within
the tumor. Negative controls consisted of staining without
applying the primary antibody and staining of a known
INI1 negative AT/RT.
Direct sequencing, reverse transcription-PCR (RT-PCR)
and Quantitative real-time reverse transcription-PCR
(qRT-PCR)
Genomic DNAs and total RNA were isolated from fresh-
frozen tumor samples by the DNeasy Blood& Tissue Kit
and RNAeasy (Qiagen) according to the manufacturer’s
instruction (Qiagen, GmbH, Germany), respectively. Gen-
omic DNAs were used to peform PCR using specific INI1
gene primers and then sequenced by direct sequencing.
For RT-PCR and qRT-PCR, 1 μg of total RNA was used to
perform reverse transcription (RT) using the RevertAid™
Reverse transcriptase kit (Cat. K1622; Fermentas, Glen
Burnie, Maryland, USA) as directed by the manufacturer.
For INI1 RT-PCR, a paired-primer encompassing exon 5
and 6 was used. For INI1, the forward primer was 5′-
AACAGGAACCGCATGGGCCG-3′, and the reverse
primer was 5′-GCCCGTGTTCCGGATGGCAA-3′ (ampli-
con size: 579 bps). For GAPDH, the forward primer was
5′-CAAGGTCATCCATGACAACTTTG-3′, and the re-
verse primer was 5′-GTCCACCACCCTGTTGCTGTAG-
3′ (amplicon size, 496 bps). Quantitative real-time PCR
reactions were performed using Maxima™ SYBR Green
qPCR Master Mix (Cat. K0222; Fermentas, Glen Burnie,
Maryland, USA), and the specific products were detected
and analyzed using the StepOne™ sequence detector
(Applied Biosystems, USA). The expression level of each
gene was normalized to GAPDH expression. For GAPDH,
the forward primer was 5′-CCAGCCGAGCCACATCGC
TC-3′ and the reverse primer was 5′-ATGAGCCCCAG
CCTTCTCCAT-3′. For SOX4, the forward primer was
5′- TCGCTGTACAAGGCGCGGAC-3′ and the reverse
primer was 5′-TTCTCCGCCAGGTGCTTGCC-3′. For
ERBB2, the forward primer was 5′- AGTACCTGGGTCT
GGACGTG-3′ and the reverse primer was 5′-CTGGGA
ACTCAAGCAGGAAG-3′. For OLIG2, the forward
primer was 5′-CAGAAGCGCTGATGGTCATA-3′ and
the reverse primer was 5′-TCGGCAGTTTTGGGTTAT
TC-3′.Array CGH (aCGH) analysis
As described in our previous study [14], the samples were
mixed with control DNA samples from healthy donors
before they were subjected to the analysis. A Human
Genome CGH Microarray Kit 244A (Agilent Technologies,
USA) with 99,000 probes and an average probe spatial reso-
lution of 15.0 kb was used. aCGH was performed according
to the protocol suggested by Agilent. Data analysis was
performed using CGH Analytics 3.4 (Agilent Technologies)
using the default parameters. Briefly, chromosomal abbrevi-
ations were calculated using the ADM2 statistic algorithm
with a moving average window of 1 Mb; additionally, the
default thresholds of ADM2 recommended by Agilent
were used to make an amplification or deletion call.
Gene expression microarray (GEM) and computational
analyses
Array data on adult neural stem cells and embryonic stem
cells were obtained in our previous study [16] and from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/) dataset GSE9940. An mRNA expression array
analysis was performed as previously described [16, 17].
Briefly, an Affymetrix™ HG-U133 Plus 2.0 whole genome
array was used. RMA log expression units were calculated
from the Affymetrix GeneChip array data with the ‘affy’
package of the Bioconductor (http://www.bioconductor.org/)
suite software for the R statistical programming language
(http://www.r-project.org/). The default RMA settings were
used to background correct, normalize and summarize all
expression values. Significant differences between sample
groups were identified by the ‘limma’ package [16]. Briefly,
a t-statistic was calculated as normal for each gene, and a
p-value was then calculated with a modified permutation
test [16]. To control for the multiple testing errors, a false
discovery rate (FDR) algorithm was then applied to these
p-values to calculate a set of q-values: thresholds of the
expected proportion of false positives or false rejections
of the null hypothesis. Heat maps were then created by
dChip software (http://www.dchip.org/). Classical multidi-
mensional scaling (MDS) was performed with the standard
function of the R program to provide a visual impression
of how the various sample groups are related. Gene anno-
tation was performed by the ArrayFusion web tool (http://
microarray.ym.edu.tw/tools/arrayfusion/) [18]. Principal com-
ponent analysis (PCA) was performed with Partek Genomics
Suite software (http://www.partek.com) to provide a visual
impression of how the various sample groups are related.
All array data have been submitted to the NCBI Gene
Expression Omnibus (GEO) database, and the accession
number is GSE65132 (Additional file 2).
MicroRNA microarray analysis
The Agilent Human miRNA Microarray Kit V2 (Agilent,
Foster City, CA, USA) containing probes for 723 human
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GeneSpring GX 9 software (Agilent, USA) was used for
value extraction. A 2-tailed Student’s t-test was then
used for the calculation of the p value for each miRNA
probe.
Results
Clinical features of the included primary pediatric
embryonal brain tumors
The diagnosis of AT/RTs and other PEBTs, especially
MBs, was based on the morphologic and IHC features
described in our previous reports (Additional file 1-A)
[7, 14]. Fresh tissues from 45 patients with PEBT (9
INI1- AT/RT, 5 INI1+ AT/RT-like, and 31 INI1+ MB)
were used in the genomics studies (Table 1). With regard
to IHC assays, EMA, VIM, SMA, GFAP and INI1 were
used as diagnostic markers, and all AT/RT or AT/RT-like
cases demonstrated positivity for at least two of these
markers (Table 2). The locations within the CNS of the
AT/RT and INI1+ AT/RT-like tumors included the cere-
bellum and the lateral ventricle. Pediatric cerebellar
MB cases were also collected as control samples, and all
of those tumors were INI1+ (Table 1). Examples of loss
(INI1-) and preservation (INI1+) of INI1 expression ac-
cording to IHC in AT/RTs and AT/RT-like cases are
shown in Fig. 1a and are as described in our previous
work [14]. The IHC results were clear because the tumor
cells were either diffusely positive or diffusely negative
(Fig. 1a). Mutations in the SMARCA4 subunit are con-
sidered alternative mutations that may be present in
AT/RT-like tumors [19, 20]; however, by IHC, we found
no SMARCA4 loss in our AT/RTs and AT/RT-like tumors
(Table 1 and Additional file 1-B).
Similar genomic DNA aberrations in INI1 (−) AT/RTs and
INI1(+) AT/RT-like cases
AT/RT cases A03-05 and A09-10, which were all INI1(−),
were used in our previous study [14]. By direct sequen-
cing, we determined that the INI1 gene region in these 5
cases was intact, while the expression of the INI1 protein
in these cases was paradoxically lost. A novel yet unidenti-
fied posttranscriptional regulatory mechanism that occurs
as part of INI1 protein synthesis likely exists in AT/RT
tumor cells [14]. We conducted a similar analysis of the
genomic DNA from cases in our current series, which in-
cluded 5 AT/RT-like tumors (L01-L02 & L06-L08, Table 1)
and an additional 4 new AT/RT cases (A11-A14, Table 1).
PCR-amplified genomic DNA samples that were isolated
from fresh-frozen tumors were used for direct INI1 gene
sequencing, and mutations were found in only two cases.
L01 (INI1+) showed a G insertion in exon 9 in one allele.
Because this insertion was located in the 3′-UTR region
of the INI1 mRNA, no abrogation of the protein would be
expected (Fig. 1b, inserted G in bold). With regard to theAT/RTs, only one case (A09), which was documented in
our previous report [14], acquired a C deletion in exon 9
in one allele (Fig. 1b). Such a deletion would lead to a
frame-shift mutation and would generate a new INI1 pro-
tein with an extra 100-aa tail (Fig. 1b, deleted C in bold
and TAA stop codon underlined). Thus, no differences in
the INI1 gene region were detected between the INI1(+)
AT/RT-like and INI1(−) AT/RT populations. RT-PCR ex-
periments confirmed the expression of INI1 transcripts in
both INI1(+) AT/RT-like cases (L01 and L08, Fig. 1c) and
INI1(−) AT/RTs [14] (A04 and A09, Fig. 1c).
Deletion of the INI1 gene, which is located at 22q11.2,
has been proposed to be a unique feature of AT/RT tumors
[3, 9]. However, our previous array CGH analysis on
Taiwanese INI1(−) AT/RT cases showed no deletion
around the INI1 gene (Table 3) [14]. We extended the
aCGH analysis to INI1(+) AT/RT-like cases, and still no
22q11.2 deletion could be found (Table 3). The INI1(+)
and INI1(−) cases shared common chromosomal aberra-
tions, including gains in 1q21.31 (150836484 ~ 150848568),
11p15.5 ~ p15.4 (274838 ~ 2917590), 11q11 (55129329 ~
55195049), 14q32.33 (105602756~ 105630148), and 22q13.31
(44813553 ~ 44849176) (Table 3). The areas that were
most commonly deleted were 7q36.1 (151592619 ~
151887233), 8p11.23 (39356595 ~ 39482044), 12p13.31
(7696275 ~ 8068377), 15q11.2 (18810004 ~ 19910926) and
21p11.1 (10117898 ~ 10144936) (Table 3). Chromosomal
aberrations in MB, including the well-known iso-17q
mutation (17p11.2 ~ q25.3, 20851757 ~ 78653717 [14],
were not detected in any of INI1(+) AT/RT-like or INI(−)
AT/RT cases, which indicates that no patients with MB
were misdiagnosed or mistaken to have INI1(+) AT/RT-
like tumors.
Distinct gene expression patterns among different
subgroups of PEBTs
To further verify that INI1(+) AT/RT-like cases were not
misdiagnosed MBs, as well as to provide new insights into
the molecular differences among MB, AT/RT, and INI1(+)
AT/RT-like cases, we examined the transcriptome patterns
of these 3 closely related embryonal brain tumors by
microarray analysis. A principle component analysis (PCA)
plot based on genes that differentiate MB and AT/RTs and
AT/RT-like cases (with a positive false discovery rate
(pFDR) threshold of q < 10−5, 496 probe sets) showed that
the AT/RT and MB cases we diagnosed were distinct from
each other at the mRNA level (Fig. 1d, Additional file 2).
Furthermore, the genetic profiles of AT/RTs and INI1(+)
AT/RT-like tumors were distinct (Fig. 1d).
With another independent MB data set published by
Kool et al. [21] (GEO database accession No. GSE10327)
as an independent cohort, we still observed distinct transcrip-
tome patterns among MBs, AT/RTs and INI1(+) AT/RT-like
tumors (Fig. 1e). We also compared the transcriptomes of
Table 1 Clinical details and INI1 IHC data of PEBT cases enrolled in aCGH and transcriptome studies
Case Age Sex Site Histo. INI1 SMARCA4 aCGH mRNA microRNA
No. (yr) Dx IHC IHC array array
L01 8.3 m cblm AT/RT-like + + + + +
L02 4.2 m cblm AT/RT-like + + + ND ND
L06 3.5 f cblm AT/RT-like + + + ND ND
L07 9.8 m cblm AT/RT-like + + + ND ND
L08 9.4 f cblm AT/RT-like + + + + +
A03 2.3 f cblm AT/RT - + + ND ND
A04 4.5 f lat. vent. AT/RT - + + + +
A05 0.1 m cblm AT/RT - + + ND ND
A09 5.2 f cblm AT/RT - + + + +
A10 1.6 m cblm AT/RT - + ND + +
A11 1.4 f cblm AT/RT - + ND + ND
A12 0.6 f cblm AT/RT - + ND + ND
A13 5 m cblm AT/RT - + ND + ND
A14 1.6 m cblm AT/RT - + ND + ND
M01 8.7 m cblm MB, cl + + + ND ND
M02 9.2 f cblm MB, an + + + ND ND
M03 4 m cblm MB, cl + + + ND ND
M04 6.3 m cblm MB, ds + + + ND ND
M05 3.5 f cblm MB, ds + + + ND ND
M06 9.4 m cblm MB, cl + + + ND ND
M07 7.6 m cblm MB, an + + + ND ND
M08 14.3 f cblm MB, cl + + + ND ND
M09 13.6 m cblm MB, cl + + + + ND
M10 12.2 f cblm MB, cl + + + ND ND
M11 4.1 f cblm MB, cl + + + + ND
M12 4.3 m cblm MB, cl + + ND + ND
M13 3.2 m cblm MB, cl + + ND + +
M14 3 m cblm MB, cl + + ND + +
M15 1.5 f cblm MB, an + + ND + +
M16 9.1 f cblm MB, an + + ND + +
M17 13 f cblm MB (*) + + ND + +
M18 18.2 m cblm MB, cl + + ND + +
M19 5.8 f cblm MB, cl + + ND + +
M20 5.1 m cblm MB, cl + + ND + +
M21 3 m cblm MB, cl + + ND + +
M22 8.5 f cblm MB, an + + ND + +
M23 2.2 m cblm MB, ds + + ND + +
M24 5.8 f cblm MB (*) + + ND + ND
M25 7.6 f cblm MB, cl + + ND + +
M26 12.2 m cblm MB, an + + ND + ND
M27 6.5 f cblm MB, an + + ND + ND
M28 2.1 m cblm MB, ds + + ND + ND
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Table 1 Clinical details and INI1 IHC data of PEBT cases enrolled in aCGH and transcriptome studies (Continued)
M29 6.3 m cblm MB, cl + + ND + ND
M30 10 m cblm MB, an + + ND + ND
Site: cblm: cerebellum, lat.vent: lateral ventricle
Histo. Dx. (Histopathological diagnosis): cl: classic, ds: demoplastic, an: anaplastic
INI1 IHC: −: loss of INI1 expression (INI1-), +: retained INI1 expression (INI1+);
SMARCA4 IHC: −: loss of SMARCA4 expression, +: retained SMARCA4 expression;
aCGH & GEM: +:performed, ND: not determined
(*)M17 with focal anaplasia; M24 with myogenic and melanocytic differentiation
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PNETs. An MDS plot showed that the transcriptomes of
either AT/RTs or INI1(+) AT/RT-like tumors were signifi-
cantly different from those of PNETs (Additional file 1-C),
which indicates that the INI1(+) AT/RT-like cases in our
series were not misdiagnosed PNETs.Stem cell traits of different groups of embryonal brain
tumors reflect their distinct clinical prognoses
To evaluate the survival outcomes of patients with AT/RTs
and INI1(+) AT/RT-like tumors, we expanded the case
numbers in the Kaplan-Meier (KM) estimator analysis.
KM analysis and a log-rank test revealed that patients with
INI1(−) AT/RTs and INI1(+) AT/RT-like tumors had a
similar overall survival rate (19 AT/RTs and 16 AT/RT-like
cases; Fig. 2a). In contrast, all 35 patients with AT/RTs or
AT/RT-like tumors had a worse overall survival than pa-
tients with MBs (P < 0.0001; Fig. 2b). It is clear that cancer
cells possess traits that are reminiscent of those ascribed
to normal stem cells and that the degree of stem cell gene
expression correlates with patient prognosis. Histologically
poorly differentiated tumors or late-stage tumors showTable 2 IHC features of AT/RT and AT/RT-like cases enrolled
Case no. INI1 EMA VIM SMA GFAP
L01 + - + + +
L02 + - + + -
L06 + + + + +
L07 + + - + +
L08 + + + + -
A03 - + + + +
A04 - + + + +
A05 - + + - +
A09 - + + + -
A10 - + + + +
A11 - + + + +
A12 - + + + +
A13 - + + + +
A14 - + + + +preferential overexpression of genes that are normally
enriched in ES cells (ESCs) or in somatic stem cells,
which may partly explain why these tumors are more ma-
lignant [22, 23]. We hypothesized that the distinct clinical
survival trends of different PEBTs might be reflected by
their gene expression traits. The array data of pluripotent
ESCs, multipotent somatic neural stem cells (NSCs) and
terminally differentiated fetal brain (FB) cells were in-
cluded in a comparative transcriptome analysis. As ex-
pected, MBs were more similar to FB tissue (Fig. 2c). The
transcriptome profiles of INI1(−) AT/RTs and INI1(+)
ATRT-like tumors were most similar to those of ESCs and
NSCs, respectively (Fig. 2c). Such impressions were quan-
tified by the measurement of the average linkage distances
between different embryonal brain tumors with respect to
ESCs, to NSCs, or to FB cells (Fig. 2d).Novel biomarkers for MBs, INI1(−) AT/RTs, and INI1(+)
AT/RT-like tumors
To identify novel biomarkers and the pathogenetic mech-
anisms of these 3 subtypes of embryonal brain tumors,
genes that are differentially expressed between each tumor
type were also identified. A gene expression heat map for
these genes indicated their unique expression patterns in
these tumor subtypes (Fig. 3a). The FGFR2 growth fac-
tor receptor, the S100A4 stemness gene and the ERBB2
(HER2/neu) oncogene were dominant in the INI1(−)
AT/RT cases (Fig. 3a, underlined). CXXC5 and SOX4
were enriched in MBs, while OLIG2, SOX6, SOX8, and
SOX10 were expressed in 2 INI1(+) AT/RT-like samples
(Fig. 3a). We also profiled the microRNA patterns in
INI1(+) AT/RT-like samples, INI1(−) AT/RTs and MBs.
Five microRNAs (miR-128, −138, −219-5p, −219-2-3p
and −346) were found to be abundantly expressed in
INI1(+) AT/RT-like cases (Fig. 3b).
Array data on OLIG2, SOX4 and ERBB2 were validated
by quantitative PCR (qPCR) (Fig. 3c-e, Additional file 2).
OLIG2 was shown to be significantly overexpressed in
INI1(+) AT/RT-like tumors (Fig. 3c), while SOX4 was
overexpressed in MBs (Fig. 3e). Such a difference in the
expression levels of these genes can be used to distinguish
MBs from AT/RTs and, more critically, can be used to
distinguish AT/RTs from INI1(+) AT/RT-like tumors.
Fig. 1 Identification of INI1(+) AT/RT-like cases among Taiwanese pediatric embryonal brain tumor cases. (a) Hematoxylin and eosin stain and
INI1 stain of pediatric AT/RT and AT/RT-like cases, one with negative INI1 immunoreactivity (left) and one with positive INI1 immunoreactivity
(right; anti-INI1, 400x). (b) Schematic representation of the results of INI1 gene sequencing. Patient A09 has only one mutated allele in the AT/RT:
a single C deletion (in bold) was detected just before the INI1 stop codon (TAA; underlined). This resulted in a frame-shift mutation. In patient
L01 with an INI1(+) AT/RT-like tumor, a single G insertion (in bold) was detected in the 3′UTR region of one INI1 allele. No protein abrogation was
expected in this case. ORF indicates the open reading frame. (c) An examination of INI1 mRNA expression in tumor tissues by RT-PCR. (d) A PCA
plot was drawn according to mRNAs that are differentially expressed between MB, AT/RT, and AT/RT-like cases (q < 10−5). INI1(+) AT/RT-like tumors
have distinct mRNA expression profiles similar to those of AT/RTs and MBs. (e) Gene expression analysis of Taiwanese INI1(+) AT/RT-like cases and
another published Caucasian MB data set. A PCA plot drawn according to the whole transcriptome again showed that INI1(+) AT/RT-like
tumors were different from MBs and INI1(−) AT/RTs (A: Wnt subgroup; B: SHH subgroup; C: subgroup which expressed neuronal differentiation
characteristic; D: subgroup which expressed neuronal and photoreceptor characteristic; E: subgroup which expressed photoreceptor characteristic and
increased protein biosynthesis/cell cycle)
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CNS AT/RTs are a specific entity of pediatric embryonic
tumors. The ability to distinguish AT/RT from MB is of
clinical significance because the reported survival rate of
patients with AT/RTs is significantly lower than that of
patients with a standard-risk MB [3]. The dismal out-
come of patients with AT/RT is due to their poor re-
sponse to conventional adjuvant therapy protocols, but
recent studies have shown that improvements in patient
survival can be achieved with intensive aggressive ther-
apy or radiotherapy as an initial treatment [6, 24, 25].Here, we report the identification of a new subtype of
AT/RT-like tumors among cases of primary pediatric
embryonal brain tumors in Taiwan and our data support
the reliability of our original pathological diagnoses.
The INI1-positive AT/RT-like subtype may not be re-
stricted to cases of PEBT in this Taiwanese population. A
recent case report from Italy illustrates an INI1(+) AT/RT
case in a 9-month-old boy whose tumor showed retained
INI1/SMARCB1 expression by IHC and lacked genetic al-
terations in the INI1 gene [19]. Instead, the tumor had a
nonsense mutation and loss of protein expression of
Table 3 Array CGH analysis showed no differential chromosomal aberration between INI1(−) AT/RTs & INI1(+) AT/RT-like cases
Array CGH results
Case No. INI1 Gain loss
L01* + 1q21.3, 11q11, 14q32.33, 8p11.23
L02 + 1q21.3, 14q32.33, 22q11.23 7q36.1, 12p13.31, 21p11.1
L06 + 1q21.3, 11q11, 22q11.23, 22q13.31 7q36.1, 12p13.31, 15q11.2, 21p11.1
L07 + 11p15.5 ~ p15.4, 14q32.33, 22q11.23, 22q13.31 7q36.1, 8p11.23, 12p13.31, 21p11.1
L08 + 11p15.5 ~ p15.4, 11q11, 14q32.33, 22q11.23, 22q13.31 15q11.2, 21p11.1
A03 - 1q21.3, 11p15.5 ~ p15.4, 11q11, 14q32.33, 22q11.23 8p11.23, 15q11.2
A04 - 11p15.5 ~ p15.4, 14q32.33, 22q13.31 7q36.1, 8p11.23, 21p11.1
A05 - 15q11.2, 21p11.1
A09** - 14q32.33, 22q11.23 7q36.1, 12p13.31
* Mutation on 1 allele; no mutation on the protein level
** Mutation on 1 allele; results in a new protein with additional 79 a.a
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complex, the ATPase subunit SMARCA4 (BRG1) due to a
homozygous SMARCA4 mutation [c.2032C >T (p.Q678X)]
[19]. Preserved INI1 protein expression and a SMARCA4
mutation were also observed in familial rhabdoid tumorFig. 2 Gene signatures reflect the clinical prognostic status of different sub
INI1(−) AT/RTs (n = 19) and INI1(+) AT/RT-like (n = 16) cases included in the
embryonal tumors (162 MBs, 19 AT/RTs, and 16 INI1(+) AT/RT-like cases) th
or AT/RT-like tumors had a worse overall survival than patients with MBs (P
expressed in the 3 subtypes of embryonal brain tumors (q < 0.001) show th
different stem or progenitor cells. ESC: embryonic stem cell; NSC: adult neu
distance between AT/RTs, MBs, INI1(+) AT/RT-like tumors and different stempredisposition syndrome (RTPS), which has been linked
to heterozygous SMARCB1 germline mutations. Two sis-
ters with RTPS whose tumors lacked mutations in INI1/
SMARCB1 were diagnosed in Germany [20]; instead of a
mutation in INI1/SMARCB1, mutations were again foundtypes of embryonal brain tumors. (a) Overall survival rates of the
IHC analysis. (b) Survival curves of 199 cases of primary pediatric CNS
at were included in the IHC validation study. All patients with AT/RTs
< 0.0001). (c) An MDS plot based on genes that are differentially
e relationships among AT/RTs, MBs, INI1(+) AT/RT-like tumors and
ral stem cell; FB: fetal brain tissues. (d) Analysis of the transcriptome
or progenitor cells. AT/RT-L: AT/RT-like
Fig. 3 Genes that distinguish AT/RTs, MBs, and INI1(+) AT/RT-like tumors. (a-b) Heat maps show group-specific genes (a) and microRNAs (b). AT/RT-L:
AT/RT-like. Red: up-regulation, Blue: down-regulation. (c-e) Real-time PCR validation of OLIG2 (c), SOX4 (D) and ERBB2 (e) array data on new batches of
patient RNAs. *P < 0.05; **P < 0.01
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SMARCA4 is a second member of the SWI/SNF complex
involved in cancer predisposition and that SMARCA4
may play an essential role in the pathogenesis of new
INI1/SMARCB1-positive AT/RT-like tumors. Whether
SMARCA4 or other proteins within the SWI/SNF chromatin-
remodeling complex are also involved in the pathogenesis
of these Taiwanese INI1(+) AT/RT-like cases is currently
under investigation.
Based on array CGH analysis, the abnormalities in the
genomic DNA of the AT/RTs and the AT/RT-like cases we
studied were indistinguishable yet distinct from those of
published MB cases [14]. The INI1 region is intact in both
INI1(+) AT/RT-like and INI1(−) AT/RT cases (Fig. 1b-c).
Genetic studies of western cohorts have shown that dele-
tion or mutation of the INI1 gene occurs in approximately75 % [3, 9] to 98 % [10] of the AT/RTs studied. Neverthe-
less, in our previous study, we found no deletion around
the INI1 gene in Taiwanese patients [14]. Subgroups of
patients with AT/RTs have tumors that express INI1
mRNA, even though the tumors in our series were nega-
tive for INI1 protein by IHC [14]. Our study reveals that a
novel yet unidentified posttranscriptional regulatory mech-
anism(s) that occurs after INI1 protein synthesis exists in
AT/RT tumor cells. The application of INI1 genomic DNA
as an essential diagnostic tool is therefore not invariably
suitable, at least in Taiwanese cases.
Tumor development, progression, and prognosis re-
main positioned at the front line of medical research.
Clinically, cancer cells with a poor differentiated patho-
logical grade usually have a worse therapeutic response
[22]. It has been demonstrated that cMyc, but not other
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program in normal and cancer cells [26]. The convergence
of dedifferentiation and cancer malignancy also comes
from the discovery that the epithelial-mesenchymal transi-
tion (EMT), which is a critical mechanism that mediates
embryogenesis and cancer metastasis, can induce the for-
mation of cancer spheres from transformed breast cancer
or colon cancer epithelial cells. This concept is also de-
rived from the discovery that tumor stem cells that have
undergone EMT are more motile and show greater meta-
static ability [27–29]. Among the three subtypes of PEBTs
that we analyzed, we also discovered distinct stem/pro-
genitor cell signatures in these tumors as well as expres-
sion levels of stemness genes that correlated well with
patient prognosis (Fig. 2). Genes that are responsible for
tumor stemness and resistance to therapy remain to be
elucidated and require further investigation.
We uncovered unique gene expression patterns among
AT/RTs, AT/RT-like tumors and MBs, and identified OLIG2
as a potential new biomarker for AT/RT-like cases (Fig. 3c).
OLIG2 is expressed in neural progenitor cells [30], which
corresponds with the finding that INI1(+) ATRT-like
tumors shared a closest transcriptome profile to that of
NSCs (Fig. 2c-d). OLIG2 also showed in subgroup of CNS-
PNET [31], but according to our PCA plot (Additional
file 1-C), they express distinct transcriptome. Therefore,
INI1 plus OLIG2 and other existed biomarkers INI1 plus
OLIG2 immunostains may help to accurately diagnose this
new AT/RT-like subtype among cases of primary PEBTs.
In addition, some genes were down-regulated in AT/RT-
like tumors, such as SRD5A1 and CREB3L4. These genes
have a chance to be biomarkers in AT/RT-like tumors, but
it still need more samples to verify.
SOX4 is a potential new biomarker for MBs. Sox4 and
Sox11, two HMG-box transcription factors, play central
regulatory roles during neuronal maturation [32]. Other
transcriptome analyses based on microarray or suppres-
sion subtraction hybridization also identified SOX4 as
an abundant protein in human MBs [33, 34]. IHC stud-
ies have verified that the Sox4 and Sox11 proteins are
strongly expressed in most classical MBs [34, 35]. Our
array and RT-qPCR series contain classical MBs, desmo-
plastic MBs and anaplastic MBs, and all cases of MB
expressed abundant SOX4 transcripts compared with
cases of INI1(+) AT/RT-like cases or INI1(−) AT/RTs.
ERBB2 (HER2/neu) was found to be overexpressed in
the AT/RT cases that we profiled. The ERBB2/HER2/neu
oncogene, the human epidermal growth factor receptor 2,
is a member of the epidermal growth factor receptor
(EGFR/ErbB) family. The amplification or over-expression
of this gene has been shown to play an important role in
the pathogenesis and progression of certain aggressive
types of breast cancer and advanced endometrioid car-
cinoma [23]. In recent years, ERBB2 has evolved tobecome an important prognostic biomarker and thera-
peutic target for breast cancer, and targeted therapies such
as Herceptin™ (trastuzumab) and Omnitarg™ (pertuzu-
mab) are now available clinically. The possibility that
existing clinical drugs can be repurposed for the treatment
of AT/RTs has yet to be evaluated.
In addition, we also find 5 miRNAs were up-regulated
in AT/RT-like tumors. MiR-138 have been reported to
serve as tumor suppressor in glioblastoma multiforme
[36] or oncomiR in malignant glioma [37], respectively.
MiR-128 and miR-219-5p are considered to be tumor sup-
pressors, since which are found to inhibit proliferation,
migration and progression in GBM [38] and gliomas
[39]. Until now, miR-346 and miR-219-2-3p don’t publish
in other brain tumor types. Therefore, miR-346 and
miR-219-2-3p have a chance to be specific biomarkers
for AT/RT-like tumors.
Conclusions
In conclusion, IHC and transcriptome studies of our pri-
mary embryonal brain tumor series identified a novel
INI1 (+) AT/RT-like subtype among Taiwanese pediatric
patients. Distinct gene expression patterns of closely re-
lated embryonal tumors were also provided. Careful diag-
nosis and clinical care of patients with different subtypes of
embryonal brain tumors will benefit daily clinical practice.
In addition, INI1(+) AT/RT-like cases are rare and hard
to collect genetic data. Therefore, a collaborative inter-
national effort needs to happen immediately, increasing
tumor numbers will help us to realize and supply specific
biomarkers to distinguish between INI1(+) AT/RT-like tu-
mors and other pediatric embryonal tumors.Additional files
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